Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group
U Athale, N Hijiya, BC Patterson… - Pediatric blood & …, 2019 - Wiley Online Library
Chronic myeloid leukemia (CML) accounts for 2‐3% of leukemias in children under 15 and
9% in adolescents aged 15‐19. The diagnosis and management of CML in children …
9% in adolescents aged 15‐19. The diagnosis and management of CML in children …
Monitoring of minimal residual disease (MRD) in chronic myeloid leukemia: recent advances
C Cumbo, L Anelli, G Specchia… - Cancer management and …, 2020 - Taylor & Francis
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1
fusion gene generation as a consequence of the t (9; 22)(q34; q11) rearrangement. The …
fusion gene generation as a consequence of the t (9; 22)(q34; q11) rearrangement. The …
[HTML][HTML] Tyrosine kinase inhibitors
RJ Thomson, M Moshirfar, Y Ronquillo - StatPearls [Internet], 2023 - ncbi.nlm.nih.gov
Tyrosine Kinase Inhibitors - StatPearls - NCBI Bookshelf US flag An official website of the
United States government Here's how you know NIH NLM Logo Access keys NCBI Homepage …
United States government Here's how you know NIH NLM Logo Access keys NCBI Homepage …
[HTML][HTML] Guidelines for cancer treatment during pregnancy: ethics-related content evolution and implications for clinicians
Simple Summary Clinical practice guidelines for cancer treatment during pregnancy have
been available for the past 20 years; however, whether they contain bioethical guidance is …
been available for the past 20 years; however, whether they contain bioethical guidance is …
Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review
A Rambhatla, MR Strug, JG De Paredes… - Journal of Assisted …, 2021 - Springer
Purpose To review the impact of tyrosine kinase inhibitors (TKIs) on fertility in men and
women, embryo development, and early pregnancy, and discuss considerations for fertility …
women, embryo development, and early pregnancy, and discuss considerations for fertility …
The argument for using imatinib in CML
S Claudiani, JF Apperley - Hematology 2014, the American …, 2018 - ashpublications.org
June 2018 was the 20th anniversary of the clinical use of the first tyrosine kinase inhibitor
(TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for …
(TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for …
Pharmacology and pharmacokinetics of imatinib in pediatric patients
M Suttorp, M Bornhäuser, M Metzler… - Expert Review of …, 2018 - Taylor & Francis
Introduction: The tyrosine kinase inhibitor (TKI) imatinib was rationally designed to target
BCR-ABL1 which is constitutively activated in chronic myeloid leukemia (CML). Following …
BCR-ABL1 which is constitutively activated in chronic myeloid leukemia (CML). Following …
Sudden blastic transformation in treatment‐free remission chronic myeloid leukaemia.
M Alfayez, G Richard‐Carpentier… - British Journal of …, 2019 - search.ebscohost.com
This phase starts after discontinuation of TKI therapy, and is characterized by continued
remission with undetectable-or stable low detectable-disease by the most sensitive method …
remission with undetectable-or stable low detectable-disease by the most sensitive method …
Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient
D Russo, M Malagola, N Polverelli… - Therapeutic …, 2023 - journals.sagepub.com
The introduction of imatinib in 2000 opened the era of tyrosine kinase inhibitors (TKIs) for
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …
A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells
Chimeric antigen receptor (CAR) T-cell immunotherapy is rapidly emerging as a promising
novel treatment for malignancies. To broaden the success of CAR T-cell treatment for …
novel treatment for malignancies. To broaden the success of CAR T-cell treatment for …